Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico

被引:18
作者
Jin, Shengming [1 ,2 ]
Wu, Junlong [1 ,2 ]
Zhu, Yao [1 ,2 ]
Gu, Weijie [1 ,2 ]
Wan, Fangning [1 ,2 ]
Xiao, Wenjun [1 ,2 ]
Dai, Bo [1 ,2 ]
Zhang, Hailiang [1 ,2 ]
Shi, Guohai [1 ,2 ]
Shen, Yijun [1 ,2 ]
Zhu, Yiping [1 ,2 ]
Ye, Dingwei [1 ,2 ]
机构
[1] Fudan Univ, Dept Urol, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 22期
基金
中国国家自然科学基金;
关键词
dear cell renal cell carcinoma; BAP1; mutation; bioinformatics; TRANSLOCATOR PROTEIN TSPO; EXPRESSION; PBRM1; SETD2; PROGNOSIS; DATABASE; OUTCOMES; TARGETS; MAPK3/1; MARKER;
D O I
10.7150/jca.27281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Aim of this study was to comprehensively analyze BRCA1-associated protein-1 (BAP1) somatic mutation in clear cell renal cell carcinoma (ccRCC) and explore potential therapeutic pathways and molecules. Patients and methods: In this study, we analyzed 445 ccRCC cases from The Cancer Genome Atlas (TCGA). Comprehensive analysis including survival, transcriptome and methylation between BAP1 mutated and wild-type cases was performed using bioinformatics tools in silico. Pathways and molecules related to BAP1 mutation were analyzed using Database for Annotation, Visualization and Integrated Discovery (DAVID) and protein-protein interaction (PPI) network. Results: BAPI mutated ccRCC patients had a worse overall survival (OS) and disease free survival (DFS) than BAP1 wild-type patients. We found 583 up-regulated and 1216 down-regulated different expressed genes (DEGs) in BAP1 mutated tumors. Up-regulated DEGs were enriched in molecular functions and biological processes like protein binding, protein transport and ubiquitin protein ligase binding. Down-regulated DEGs were enriched in pathways like Rapt signaling pathway, Notch pathway and altered molecular functions like metal ion binding and ubiquitin-protein transferase activity. Furthermore, CAD, TSPO, CTNNB1 and MAPK3 were top hub genes selected using PPI network analysis. Finally, BAP1 mutation had a strong correlation with CpG island methylator phenotype (CIMP). Conclusion: Our study provides a comprehensive understanding of BAP1 functional somatic mutation in ccRCC patients. Several hub genes like CAD and TSPO may become potential therapeutic targets.
引用
收藏
页码:4108 / 4116
页数:9
相关论文
共 50 条
  • [21] Effects of BAP1, Ki-67 index, and Id-1 in patients with clear cell renal carcinoma and their correlation with clinical features and prognosis
    Yang, Jing
    Gong, Chunyu
    Zhao, Juan
    Chen, Lan
    Mei, Xuefeng
    Li, Guangsen
    Cai, Jian
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (05) : 2242 - 2250
  • [22] Comprehensive Analysis of the Role of CXCL Family Members in Clear Cell Renal Cell Carcinoma
    Qiu, Jiechuan
    Wang, Zicheng
    Zhang, Peizhi
    Xu, Yingkun
    Yang, Tianmin
    Xia, Qinghua
    CURRENT CANCER DRUG TARGETS, 2024,
  • [23] Stabilization of MCRS1 by BAP1 prevents chromosome instability in renal cell carcinoma
    Peng, Jingtao
    Ma, Jian
    Li, Weiguo
    Mo, Ren
    Zhang, Pingzhao
    Gao, Kun
    Jin, Xiaofeng
    Xiao, Jiantao
    Wang, Chenji
    Fan, Jie
    CANCER LETTERS, 2015, 369 (01) : 167 - 174
  • [24] Identification of biomarkers and potential molecular mechanisms of clear cell renal cell carcinoma
    Wu, F.
    Wu, S.
    Gou, X.
    NEOPLASMA, 2018, 65 (02) : 242 - 252
  • [25] Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma
    Bai, Jianrong
    Zheng, Axiu
    Ha, Yanping
    Xu, Xiaoqing
    Yu, Yaping
    Lu, Yanda
    Zheng, Shaojiang
    Shen, Zhihua
    Luo, Botao
    Jie, Wei
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [26] BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies
    Piva, Francesco
    Santoni, Matteo
    Matrana, Marc R.
    Satti, Suma
    Giulietti, Matteo
    Occhipinti, Giulia
    Massari, Francesco
    Cheng, Liang
    AntonioLopez-Beltran
    Scarpelli, Marina
    Principato, Giovanni
    Cascinu, Stefano
    Montironi, Rodolfo
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (09) : 1201 - 1210
  • [27] Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma
    Liu, Tong
    Sui, Jing
    Zhang, Yan
    Zhang, Xiao-Mei
    Wu, Wen-Juan
    Yang, Sheng
    Xu, Si-Yi
    Hong, Wei-Wei
    Peng, Hui
    Yin, Li-Hong
    Pu, Yue-Pu
    Liang, Ge-Yu
    ONCOLOGY REPORTS, 2018, 40 (03) : 1503 - 1514
  • [28] BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
    Friedhoff, Jana
    Schneider, Felix
    Jurcic, Christina
    Endris, Volker
    Kirchner, Martina
    Sun, Angela
    Bolnavu, Iulia
    Pohl, Laura
    Teroerde, Miriam
    Kippenberger, Maximilian
    Schwab, Constantin
    Kaczorowski, Adam
    Zschaebitz, Stefanie
    Jaeger, Dirk
    Hohenfellner, Markus
    Stenzinger, Albrecht
    Duensing, Anette
    Duensing, Stefan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1603 - 1618
  • [29] Integrated bioinformatics analysis for the identification of potential key genes affecting the pathogenesis of clear cell renal cell carcinoma
    Cui, Hao
    Xu, Lei
    Li, Zhi
    Hou, Ke-Zuo
    Che, Xiao-Fang
    Liu, Bo-Fang
    Liu, Yun-Peng
    Qu, Xiu-Juan
    ONCOLOGY LETTERS, 2020, 20 (02) : 1573 - 1584
  • [30] BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
    Jana Friedhoff
    Felix Schneider
    Christina Jurcic
    Volker Endris
    Martina Kirchner
    Angela Sun
    Iulia Bolnavu
    Laura Pohl
    Miriam Teroerde
    Maximilian Kippenberger
    Constantin Schwab
    Adam Kaczorowski
    Stefanie Zschäbitz
    Dirk Jäger
    Markus Hohenfellner
    Albrecht Stenzinger
    Anette Duensing
    Stefan Duensing
    Cancer Immunology, Immunotherapy, 2023, 72 : 1603 - 1618